Investor News

SNP confirms preliminary figures for the third quarter 2024

  • Order entry increased by 24% to €74.9 million (Q3 2023: €60.2 million)
  • Group revenue grew by 24% to €66.8 million (Q3 2023: €54.1 million)
  • EBIT margin climbed to 12.2% (Q3 2023: 8.9%)
Investor News

SNP reports record Q2 2024 results

  • Order entry increased by 45% to € 74.1 million (Q2 2023: € 51.0 million)
  • Group revenue rose by 28% to € 62.0 million (Q2 2023: €48.5 million)
  • EBIT improved significantly by € 7.4 million to € 8.4 million (Q2 2023: €1.0 million), EBIT margin to 13.6% (Q2 2023: 2.1%)
IR-banner-v0-960x500.jpg

Publications


Here you will find financial and annual reports, presentations and recordings of our investor and analyst conferences.

You can also use our e-mail distribution list to make sure you don't miss any SNP capital market information in the future.

Contact

Publications.svg

Our Archive

Voluntary public takeover offer

SNP: Public Takeover Offer Completed – Transition to Dualistic Management System Planned 

Link

Joint Statement of the Board of Directors and the Managing Directors (in German only)

Download

Press Release Joint Statement of the Board of Directors and the Managing Directors

Download

For information on the voluntary public takeover offer and contact details please consult the Octapharma AG website at:

Read more

Voluntary public takeover offer

SNP: Public Takeover Offer Completed – Transition to Dualistic Management System Planned 

Link

Joint Statement of the Board of Directors and the Managing Directors (in German only)

Download

Press Release Joint Statement of the Board of Directors and the Managing Directors

Download

For information on the voluntary public takeover offer and contact details please consult the Octapharma AG website at:

Read more